Data from the phase 3 SIERRA trial of Iomab-B presented at the annual European Association of Nuclear Medicine (EANM) Congress 2024
Stockholm, October 25, 2024 – Immedica is pleased to announce that data from the Phase 3 SIERRA trial of Iomab-B…
1,716€
9,72%
Echtzeit-Aktienkurs Actinium Pharmaceuticals Inc.
Bid:
Ask:
Nachrichten zur Actinium Pharmaceuticals Inc. Aktie
NRx Pharmaceuticals, Inc. (NRXP) Q2 2024 Earnings Call Transcript
…
Immedica’s partner Actinium announces Iomab-B phase 3 SIERRA trial results in patients with TP53 mutation at the EHA 2024 Annual Congress
Stockholm, June 15, 2024 - Immedica’s partner Actinium Pharmaceuticals, Inc. announced results from the Phase 3 SIERRA trial of Iomab-B in…
NRx Pharmaceuticals, Inc. (NRXP) Q1 2024 Earnings Call Transcript
…
Actinium Pharmaceuticals advances in medical isotope production By Investing.com
Actinium Pharmaceuticals advances in medical isotope production…
Immedica’s partner Actinium presented four abstracts of Iomab-B at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®
Stockholm, February 27, 2024 – Immedica’s partner Actinium Pharmaceuticals, Inc. presented four abstracts at the 2024 Tandem Meetings | Transplantation…
Radiotheranostics Market Current Trends and Future Scope Analysis Report
Companies covered in this report are TransCode Therapeutics, Inc., Curium SAS, GE Healthcare Inc., Bayer AG, Lantheus Medical, Imaging, Inc.,…
BUSINESS WIRE: Nordic Pharma Group B.V. schließt über ihre Tochtergesellschaft Amring Pharmaceuticals Inc. die Übernahme von Visant Medical ab, um in den Vereinigten Staaten eine neuartige Therapie für trockene Augen einzuführen
MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.BERWYN, Pennsylvania --(BUSINESS WIRE)-- 18.12.2023 --Amring Pharmaceuticals…
Immedica’s partner Actinium announces oral presentation at ASH annual meeting on Iomab-B outcomes data for TP53 gene mutation from the SIERRA trial
Stockholm, November 14 , 2023 – Immedica’s partner Actinium Pharmaceuticals, Inc. has announced that three abstracts detailing results from the…
Actinium Pharmaceuticals: The Trickle Down Continues, And I Maintain A Buy
…
I131-apamistamab SIERRA abstracts accepted for oral and poster presentation at the European Association of Nuclear Medicine 2023 Congress
Stockholm, August 25, 2023 – Immedicas partner Actinium Pharmaceuticals, Inc. has announced that two abstracts have been accepted for oral…
Form 10-Q Actinium Pharmaceuticals For: Jun 30
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
PanTera and TerraPower Isotopes join forces to accelerate access to actinium-225
Strategic collaboration signed to support...…
NIT Research: Nano Imrad Technology Announces Availability of Actinium-225, Pioneering a New Era of Cancer Treatment
Beginning in the second quarter of 2023, NIT will provide Actinium-225 in millicurie quantities, marking a significant step forward in…
Form 10-Q Actinium Pharmaceuticals For: Mar 31
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Actinium Pharma to Present at Guggenheim Healthcare Talks Radiopharmaceuticals Day
NEW YORK, May 10, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in…
Actinium Pharmaceuticals: Actinium Announces Positive Phase 3 Trial Results, NCI CRADA For AML Drug Candidates - Could They Become New Standards Of Care For This Deadly Disease?
NEW YORK, NY / ACCESSWIRE / April 21, 2023 / Patients with relapsed or refractory (r/r) acute myeloid leukemia (AML)…
Corporate News: Eckert & Ziegler Strahlen- und Medizintechnik AG
Eckert & Ziegler beliefert POINT Biopharma mit Actinium-225...…
Actinium Pharmaceuticals Reports 2022 Financial Results and Highlights Recent and Upcoming Clinical Data and Milestones
- Announced positive results from the pivotal Phase 3 SIERRA trial of Iomab-B in r/r AML patients ages 55+; achieved…
Form 8-K Actinium Pharmaceuticals For: Mar 10
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Thinking about buying stock in Apellis Pharmaceuticals, Vir Biotechnology, Actinium Pharmaceuticals, Arbe Robotics, or Sigma Lithium?
NEW YORK, Feb. 21, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APLS, VIR, ATNM, ARBE, and SGML. To…
Form 8-K Actinium Pharmaceuticals For: Feb 18
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Actinium Pharmaceuticals Shares Rise 21% After Positive Iomab-B Trial
Actinium Pharmaceuticals Shares Rise 21% After Positive Iomab-B Trial...…
Actinium Announces Positive Full Data Results From the Pivotal Phase 3 SIERRA Trial in Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia
- Iomab-B met the primary endpoint of durable Complete Remission (dCR) of 6-months following initial complete remission after BMT with…
Fusion Pharmaceuticals Reports Progress and Provides Recent Corporate Highlights
FPI-2068 IND expected to be submitted in the first quarter of 2023 FPI-1434 Phase 1 data expected in the second…
Fusion Pharmaceuticals and BWXT Medical Announce Actinium-225 Partnership to Scale Supply for Developing Targeted Alpha Therapies
- Agreement augments Fusions existing isotope supply as pipeline of clinical stage actinium-based radiopharmaceuticals grows - Furthers BWXT Medicals position…
Form 8-K Actinium Pharmaceuticals For: Dec 30
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 8-K Actinium Pharmaceuticals For: Dec 08
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Actinium sheds 15% after shareholder letter
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Actinium Pharmaceuticals Shares Fall on Delayed Iomab-B Drug Study Data Release >ATNM
Actinium Pharmaceuticals Shares Fall on Delayed Iomab-B Drug Study Data Release >ATNM...…
Form 10-Q Actinium Pharmaceuticals For: Sep 30
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Actinium Announces Positive 1-Year and 2-Year Overall Survival Data for Patients with Relapsed or Refractory AML in Phase 1 Actimab-A CLAG-M Combination Trial
53% 1-year Overall Survival and 32% 2-year Overall Survival are approximately double outcomes with current approaches Patients on study received…
Actinium Appoints Seasoned Leader Caroline Yarbrough as Chief Commercial Officer to Spearhead Iomab-B Commercialization
-Caroline joins Actinium from Novartis where she served as Portfolio General Manager, US Oncology -Proven commercial leadership experience spans hematology,…
Actinium Pharma Shares Hit 52-Week High After Positive Results for Iomab-B
Actinium Pharma Shares Hit 52-Week High After Positive Results for Iomab-B...…
Actiniums stock jumps 22% on new data for its acute myeloid leukemia therapy
Shares of Actinium Pharmaceuticals Inc. were up 22.8% in trading on Monday after the company met the primary endpoint…
Actinium Pharmaceuticals stock price target raised to $35 from $25 at Maxim Group
Um den gesamten Artikel unter marketwatch.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 8-K Actinium Pharmaceuticals For: Oct 31
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Actinium climbs 23% as lead asset meets main goal in Phase 3 leukemia trial
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Actinium Pharmaceuticals Sees Positive Data From Iomab-B Trial
Actinium Pharmaceuticals Sees Positive Data From Iomab-B Trial...…
Actinium Announces Positive Top-line Results from Pivotal Phase 3 SIERRA Trial of Iomab-B in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia
- Iomab-B met the primary endpoint of durable complete remission of 6-months following initial complete remission after HCT with a…
Actinium Expands Clinical Leadership Team to Support Key Development Programs for Iomab-B and Actimab-A
Key hires with proven expertise and track records in Bone Marrow Transplant, Acute Myeloid Leukemia, Radiation Sciences and Clinical Operations…
Actinium Pharmaceuticals to Participate in the 2022 Bio-Europe Conference
NEW YORK, Oct. 26, 2022 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company) a leader in…
Actinium Bolsters its Senior Leadership Team Ahead of Upcoming Clinical Data for Iomab-B
Jenny Hsieh joins Actinium as Chief Strategy Officer from Gilead Sciences, following its acquisition of Immunomedics Sunitha Lakshminarayanan, Senior Vice…
Corporate News: Eckert & Ziegler Strahlen- und Medizintechnik AG
Eckert & Ziegler und Alpha-9 Unterzeichnen Reservierungsvereinbarung für Actinium-225...…